Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Capstone Therapeutics ( (CAPS) ) has shared an announcement.
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes. On October 22, 2025, Capstone issued a second convertible note worth $3,545,712.42, convertible into common stock at a price of $1.10 per share. The company received gross proceeds of $3,250,000 from this issuance and plans to file a registration statement with the SEC for the resale of the stock. Joseph Gunnar & Co., LLC acted as the sales agent for this financing.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, negative equity, and high leverage. Technical analysis indicates a bearish trend, while valuation metrics are unattractive due to ongoing losses. The absence of earnings call and corporate events data did not influence the score.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 2,401,727
Technical Sentiment Signal: Sell
Current Market Cap: $6.75M
See more insights into CAPS stock on TipRanks’ Stock Analysis page.